Terms: = Thyroid cancer AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1 AND Treatment
27 results:
1. Fibronectin Contributes to a BRAF Inhibitor-driven Invasive Phenotype in thyroid cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2.
Hicks HM; Pozdeyev N; Sams SB; Pugazhenthi U; Bales ES; Hofmann MC; McKenna LR; Schweppe RE
Mol Cancer Res; 2023 Sep; 21(9):867-880. PubMed ID: 37219859
[TBL] [Abstract] [Full Text] [Related]
2. Novel Therapeutics for Advanced Differentiated thyroid cancer.
Lieberman L; Worden F
Endocrinol Metab Clin North Am; 2022 Jun; 51(2):367-378. PubMed ID: 35662446
[TBL] [Abstract] [Full Text] [Related]
3. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update.
Roskoski R
Pharmacol Res; 2021 Mar; 165():105463. PubMed ID: 33513356
[TBL] [Abstract] [Full Text] [Related]
4. BRAF
Traversi F; Stooss A; Dettmer MS; Charles RP
Thyroid; 2021 May; 31(5):787-799. PubMed ID: 33012268
[No Abstract] [Full Text] [Related]
5. Selumetinib: First Approval.
Markham A; Keam SJ
Drugs; 2020 Jun; 80(9):931-937. PubMed ID: 32504375
[TBL] [Abstract] [Full Text] [Related]
6. Exogenous Hydrogen Sulfide Regulates the Growth of Human thyroid Carcinoma Cells.
Wu D; Li J; Zhang Q; Tian W; Zhong P; Liu Z; Wang H; Wang H; Ji A; Li Y
Oxid Med Cell Longev; 2019; 2019():6927298. PubMed ID: 31223424
[TBL] [Abstract] [Full Text] [Related]
7. KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary thyroid cancer.
Owen DH; Konda B; Sipos J; Liu T; Webb A; Ringel MD; Timmers CD; Shah MH
J Natl Compr Canc Netw; 2019 May; 17(5):409-413. PubMed ID: 31085763
[TBL] [Abstract] [Full Text] [Related]
8. Mitochondrial metabolism is inhibited by the HIF1α-MYC-PGC-1β axis in BRAF V600E thyroid cancer.
Gao Y; Yang F; Yang XA; Zhang L; Yu H; Cheng X; Xu S; Pan J; Wang K; Li P
FEBS J; 2019 Apr; 286(7):1420-1436. PubMed ID: 30768848
[TBL] [Abstract] [Full Text] [Related]
9. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
[TBL] [Abstract] [Full Text] [Related]
10. Long glucocorticoid-induced leucine zipper regulates human thyroid cancer cell proliferation.
Ayroldi E; Petrillo MG; Marchetti MC; Cannarile L; Ronchetti S; Ricci E; Cari L; Avenia N; Moretti S; Puxeddu E; Riccardi C
Cell Death Dis; 2018 Feb; 9(3):305. PubMed ID: 29467389
[TBL] [Abstract] [Full Text] [Related]
11. Individualized drug screening based on next generation sequencing and patient derived xenograft model for pancreatic cancer with bone metastasis.
Guan Z; Lan H; Chen X; Jiang X; Wang X; Jin K
Mol Med Rep; 2017 Oct; 16(4):4784-4790. PubMed ID: 28849200
[TBL] [Abstract] [Full Text] [Related]
12. Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.
Wang W; Zhou J; Zhao L; Chen S
Biomed Pharmacother; 2017 Apr; 88():985-990. PubMed ID: 28178630
[TBL] [Abstract] [Full Text] [Related]
13. Thyrotropin and Insulin-Like Growth Factor 1 Receptor Crosstalk Upregulates Sodium-Iodide Symporter Expression in Primary Cultures of Human Thyrocytes.
Morgan SJ; Neumann S; Marcus-Samuels B; Gershengorn MC
Thyroid; 2016 Dec; 26(12):1794-1803. PubMed ID: 27638195
[TBL] [Abstract] [Full Text] [Related]
14. The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in thyroid cancer.
Beadnell TC; Mishall KM; Zhou Q; Riffert SM; Wuensch KE; Kessler BE; Corpuz ML; Jing X; Kim J; Wang G; Tan AC; Schweppe RE
Mol Cancer Ther; 2016 Aug; 15(8):1952-63. PubMed ID: 27222538
[TBL] [Abstract] [Full Text] [Related]
15. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
[TBL] [Abstract] [Full Text] [Related]
16. Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor.
Yeung SF; Tong JHM; Law PPW; Chung LY; Lung RWM; Tong CYK; Chow C; Chan AWH; Wan IYP; Mok TSK; To KF
J Thorac Oncol; 2015 Sep; 10(9):1292-1300. PubMed ID: 26098749
[TBL] [Abstract] [Full Text] [Related]
17. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations.
Smith N; Nucera C
J Clin Endocrinol Metab; 2015 Jan; 100(1):35-42. PubMed ID: 25347569
[TBL] [Abstract] [Full Text] [Related]
18. MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro.
Angell TE; Lechner MG; Jang JK; LoPresti JS; Epstein AL
Clin Cancer Res; 2014 Dec; 20(23):6034-44. PubMed ID: 25294906
[TBL] [Abstract] [Full Text] [Related]
19. Phosphoproteomics of MAPK inhibition in BRAF-mutated cells and a role for the lethal synergism of dual BRAF and CK2 inhibition.
Parker R; Clifton-Bligh R; Molloy MP
Mol Cancer Ther; 2014 Jul; 13(7):1894-906. PubMed ID: 24825855
[TBL] [Abstract] [Full Text] [Related]
20. Copper is required for oncogenic BRAF signalling and tumorigenesis.
Brady DC; Crowe MS; Turski ML; Hobbs GA; Yao X; Chaikuad A; Knapp S; Xiao K; Campbell SL; Thiele DJ; Counter CM
Nature; 2014 May; 509(7501):492-6. PubMed ID: 24717435
[TBL] [Abstract] [Full Text] [Related]
[Next]